Core Insights - Intuitive Surgical (ISRG) is focusing on cardiac surgery as a long-term growth opportunity for the da Vinci 5 platform following recent FDA regulatory approvals [2][3] - The company estimates an immediate opportunity for the da Vinci 5 system at approximately 160,000 annual cardiac procedures in cleared markets, compared to around 17,000 procedures performed globally using older da Vinci systems in 2025 [3][6] - The approach to the cardiac segment will be cautious, involving a gradual rollout supported by specialized training and collaboration with surgical societies [4][6] Company Initiatives - Intuitive Surgical is developing cardiac-specific instrumentation and technologies, including Force Feedback instruments, to enhance the capabilities of the da Vinci 5 system [5][6] - The company is refining digital tools to support procedure planning and intraoperative guidance, aiming to facilitate broader surgeon adoption of robotic cardiac procedures [5][6] - The initiatives suggest that while cardiac surgery may not be a near-term revenue driver, it could significantly expand ISRG's total addressable market (TAM) over the long term [6] Peer Updates - Zimmer Biomet (ZBH) is positioning its ROSA robotic platform for long-term growth through expanding clinical indications and technology integration, with strong sales and increasing adoption in robotic-assisted orthopedics [7][8] - Stryker (SYK) is accelerating the clinical scope of its Mako robotic system, with record installations and expanding indications into advanced primary hips, revision hips, and spine procedures [9][10] Financial Performance - ISRG shares have increased by 12.9% over the past six months, outperforming the industry, which saw a decline of 3.2% [12] - The forward price-to-earnings ratio for Intuitive Surgical is 47.74, above the industry average but lower than its five-year median of 70.97 [13] - The Zacks Consensus Estimate for ISRG's 2026 earnings indicates a 12.7% increase compared to the previous year [14]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 10.3% year-over-year to $335.4 million, nearing the top end of the guidance range of $320 million to $340 million [18][19] - Fourth quarter revenue was reported at $108.8 million, representing a 56.4% increase year-over-year [19] - Gross margin for the fourth quarter improved to 9.6%, with potential gross margin in the mid-20% range if excluding unfavorable impacts from EACs [21][22] - The company ended 2025 with total liquidity of $130.2 million, a significant year-over-year improvement [24] Business Line Data and Key Metrics Changes - The space segment recorded revenue of $54.5 million, while the DefTech segment recorded revenue of $54.3 million in the fourth quarter [20] - Book-to-bill ratio for the fourth quarter was 1.52, with space bookings at $110.9 million and DefTech bookings at $54 million [26] - The company ended 2025 with a record contracted backlog of $411.2 million, supported by strong bookings [5][26] Market Data and Key Metrics Changes - The company expanded its customer base to over 170 civil, national security, and commercial space and defense tech customers [5] - The backlog for the space segment was $299.8 million, while the DefTech backlog was $111.4 million as of December 31, 2025 [27] Company Strategy and Development Direction - Redwire transformed from a pure-play space provider to a multi-domain space and defense tech company, following the acquisition of Edge Autonomy [4][5] - The company plans to invest heavily in advancing critical technologies with high growth potential, such as VLEO and quantum satellites [9] - Redwire will be organized into two business segments: Space and Defense Tech, to enhance visibility and growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth through 2026, supported by a record backlog and a strengthened balance sheet [30] - The company anticipates full year 2026 revenue to be in the range of $450 million to $500 million, representing a 41.6% year-over-year growth rate at the midpoint [28] Other Important Information - The company significantly increased its investment in research and development from $1.4 million in 2024 to $9.5 million in 2025 [23] - Redwire repaid a net $125.5 million of debt during 2025, resulting in estimated annual interest savings of more than $17 million [24][25] Q&A Session Summary Question: How is management adjusting its pricing model in response to the low gross margin throughout 2025? - Management indicated that they are meeting customers' contracting preferences and balancing their portfolio to improve margins while still pursuing market share [32][34] Question: Do you have any insight on how many aircraft standalone Edge did in 2024? - Management confirmed that Edge delivered about 200 aircraft in 2024, with 100 aircraft delivered since the acquisition [39][40] Question: How much of the backlog is expected to be executed over the next 12 months? - Approximately 50% of the backlog is expected to be executed in 2026, with no single orders that would materially impact revenue [49][51] Question: What are you seeing in the broader order environment? - Management noted a positive trend in contract awards, with larger orders contributing to the backlog and a faster conversion cycle for DefTech compared to space [55][58] Question: Is there a material part of defense that's not related to the Edge Autonomy acquisition? - Management confirmed that the DefTech segment includes legacy capabilities beyond Edge Autonomy, such as space optics and RF systems [64][66]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 10.3% year-over-year to $335.4 million, nearing the top end of the guidance range of $320 million to $340 million [18][19] - Fourth quarter revenue was reported at $108.8 million, representing a 56.4% increase year-over-year [19] - Gross margin for the fourth quarter improved to 9.6%, with potential gross margin in the mid-20% range if excluding unfavorable impacts from EACs [21][22] - The company ended 2025 with a record total liquidity of $130.2 million, including $94.5 million in cash [24] Business Line Data and Key Metrics Changes - The space segment recorded revenue of $54.5 million, while the defense tech segment recorded revenue of $54.3 million in the fourth quarter [20] - Book-to-bill ratio for the fourth quarter was 1.52, with space bookings at $110.9 million and defense tech bookings at $54 million [26] - The company ended 2025 with a record contracted backlog of $411.2 million, with space backlog at $299.8 million and defense tech backlog at $111.4 million [27] Market Data and Key Metrics Changes - The company expanded its customer base to over 170 civil, national security, and commercial space and defense tech customers [5] - The acquisition of Edge Autonomy contributed significantly to the defense tech segment's revenue growth [20] Company Strategy and Development Direction - Redwire transformed from a pure-play space provider to a multi-domain space and defense tech company, integrating Edge Autonomy into its brand [4][5] - The company plans to invest heavily in advancing critical technologies with high growth potential, such as VLEO and quantum satellites [9] - Redwire will be organized into two business segments: Space and Defense Tech, to enhance visibility and growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth through 2026, supported by a record backlog and a strengthened balance sheet [30] - The company anticipates full year 2026 revenue to be in the range of $450 million to $500 million, representing a 41.6% year-over-year growth rate at the midpoint [28] Other Important Information - The company significantly increased its R&D spending from $1.4 million in 2024 to $9.5 million in 2025, reflecting confidence in market signals [23] - Redwire repaid a net $125.5 million of debt during 2025, resulting in estimated annual interest savings of more than $17 million [24][25] Q&A Session Summary Question: How is management adjusting its pricing model in response to the low gross margin throughout 2025? - Management indicated that they are meeting customers' contracting preferences and balancing their portfolio to include both development contracts and production programs, expecting gross margin improvements as production scales [32][34][35] Question: Do you have any insight on how many aircraft standalone Edge did in 2024? - Management confirmed that Edge delivered about 200 aircraft in 2024, with 100 aircraft delivered since the acquisition [38][39] Question: How much of the backlog is expected to be executed over the next 12 months? - Approximately 50% of the backlog is expected to be executed in 2026, with no single orders that would materially impact revenue [49][51] Question: What are the expectations for book-to-bill in 2026? - Management noted that the order cycles differ between space and defense tech, with space having a longer backlog conversion cycle compared to the faster conversion for defense tech [56][58] Question: Is there a material part of defense that is not related to the Edge Autonomy acquisition? - Management confirmed that the defense tech segment includes legacy capabilities beyond Edge Autonomy, such as space optics and RF systems [64][65]

Financial Data and Key Metrics Changes - Revenue for 2025 increased by 10.3% year-over-year to $335.4 million, nearing the top end of the guidance range of $320 million to $340 million [17][18] - Fourth quarter revenue was reported at $108.8 million, representing a 56.4% increase year-over-year [18][19] - Gross margin for the fourth quarter improved to 9.6%, with potential gross margin in the mid-20% range if not for unfavorable impacts from EACs [19][20] - The company ended 2025 with total liquidity of $130.2 million, a significant year-over-year improvement [22] Business Line Data and Key Metrics Changes - The space segment recorded revenue of $54.5 million, while the DefTech segment recorded revenue of $54.3 million in the fourth quarter [19] - Book-to-bill ratio for the fourth quarter was 1.52, with space bookings at $110.9 million and DefTech bookings at $54 million [24][25] - The company ended 2025 with a record contracted backlog of $411.2 million, supported by strong bookings [4][24] Market Data and Key Metrics Changes - The company expanded its customer base to over 170 civil, national security, and commercial space and defense tech customers [4] - The backlog for the space segment was $299.8 million, while the DefTech backlog was $111.4 million as of December 31, 2025 [25] Company Strategy and Development Direction - Redwire transformed from a pure-play space provider to a multi-domain space and defense tech company, integrating Edge Autonomy into its brand [3][4] - The company plans to invest heavily in advancing critical technologies with high growth potential, such as VLEO and quantum satellites [8][9] - Redwire will be organized into two business segments: Space and Defense Tech, to enhance visibility and growth [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth through 2026, supported by a record backlog and a strengthened balance sheet [27] - The company anticipates full year 2026 revenue to be in the range of $450 million to $500 million, representing a 41.6% year-over-year growth rate at the midpoint [26] Other Important Information - The company significantly increased its investment in research and development from $1.4 million in 2024 to $9.5 million in 2025 [21] - Redwire repaid a net $125.5 million of debt during 2025, resulting in estimated annual interest savings of more than $17 million [22][23] Q&A Session Summary Question: How is management adjusting its pricing model in response to the low gross margin throughout 2025? - Management indicated that they are meeting customers' contracting preferences and balancing their portfolio to improve margins while still pursuing market share [30][32] Question: Do you have any insight on how many aircraft standalone Edge did in 2024? - Management confirmed that Edge delivered about 200 aircraft in 2024, with 100 aircraft delivered since the acquisition [36][38] Question: How much of the backlog is expected to be executed in 2026? - Approximately 50% of the backlog is expected to be executed in 2026, with no single orders that would significantly impact revenue [47][49] Question: What are the expectations for book-to-bill in 2026? - Management noted that the order cycles differ between space and DefTech, with space having a longer backlog conversion cycle compared to the faster conversion for DefTech [53][56] Question: Is there a material part of defense that is not from the Edge Autonomy acquisition? - Management confirmed that DefTech includes legacy capabilities beyond Edge Autonomy, such as space optics and RF systems [61][62]

INVESTOR UPDATE Q4 and FY25 FEBRUARY 26, 2026 USE OF DATA Industry and market data used in this Presentation have been obtained from third-party industry publications and sources, as well as from research reports prepared for other purposes. Redwire has not independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change. Statements other than historical facts, including, but not limited to, those concerning market condi ...

Core Insights - Intuitive Surgical (ISRG) reported strong 2025 results, with total revenues increasing by 20.5% year over year to $10.1 billion and adjusted earnings per share rising by 21.7% to $8.93, driven by higher procedure volumes and increased utilization of its robotic systems [1][10] Financial Performance - Total revenues for 2025 reached $10.1 billion, marking a 20.5% increase year over year [1] - Adjusted earnings per share were $8.93, reflecting a 21.7% growth [1] - The company treated over 3.1 million patients in 2025, an 18% increase from the previous year [1] Growth Drivers - The growth was primarily fueled by higher procedure volumes, supported by an expanding installed base and increased utilization of da Vinci platforms, which saw a global utilization increase of 3% [1] - The Instruments and accessories segment experienced an 18.5% sales growth, driven by the adoption of the da Vinci 5 robotic system and its expansion into new surgical indications [2] Future Outlook - For 2026, Intuitive Surgical anticipates worldwide procedure growth of approximately 13-15%, which is lower than the growth rate in 2025 but reflects an upward revision from previous expectations [5][10] - The company plans to focus on global expansion of its robotic platforms, particularly the da Vinci 5, and will increase investments in training, commercial execution, and market access [3] - The recent FDA clearance for da Vinci 5 for certain cardiac procedures is expected to expand the total addressable market by approximately 160,000 procedures annually [3] Product Development - Intuitive Surgical intends to introduce additional products and features in 2026 to enhance the capabilities of the da Vinci 5 system, potentially driving further growth in procedure volumes [4] Market Position - ISRG's stock has seen a 0.9% increase over the past six months, compared to a 2.8% growth for the industry [9] - The company trades at a forward price-to-earnings ratio of 47, which is above the industry average but lower than its five-year median of 71.33 [11]

Core Insights - The company provided a year-end corporate update reflecting on its execution, market conditions, and strategic positioning as it enters 2026 [1] Group 1: Execution and Team Focus - Throughout 2025, the company prioritized supporting its team, delivering customer value, maintaining product quality, advancing sales execution, and investing in targeted research and development [2] - The company operated in a challenging macroeconomic environment characterized by inflation, elongated purchasing cycles, and delayed capital spending decisions, yet maintained operational continuity and improved sales momentum by year-end [3][6] Group 2: Customer Satisfaction and Sales Progress - The company emphasized customer satisfaction, with positive client feedback reinforcing the value of its AI-enabled security platforms and collaborative approach [5] - Although early 2025 revenue performance did not meet expectations, improved sales execution was noted in the second half, with new enterprise customers onboarded and existing client deployments expanded [6][7] Group 3: Product Portfolio and Financial Discipline - The company invested selectively in its technology ecosystem, focusing on scalability, reliability, and margin efficiency, with key products including SARA, ROAMEO, ROSA, RIO, AVA, and RADCam [8] - Financial discipline was maintained throughout 2025, with cost management and continued investment in growth initiatives, alongside updates to the employee stock option plan to align incentives with long-term shareholder value [9] Group 4: Future Outlook - Entering 2026, the company is supported by a stabilized team, improving sales traction, and a focused product roadmap, positioning itself to translate efforts into results [10] - The company operates within a nearly $50 billion security and guarding services industry, offering AI-driven solutions that provide significant cost savings compared to traditional manned security [11]

Core Insights - Intuitive Surgical's (ISRG) third-quarter results show a 20% year-over-year increase in combined da Vinci and Ion procedures, raising questions about the sustainability of this growth rate [2][6] Company Performance - da Vinci procedures grew by 19%, while Ion volumes surged by 52%, with growth observed across various surgical fields including general surgery, gynecology, and international markets [3] - The introduction of da Vinci 5 has led to higher utilization rates compared to previous Xi systems, with U.S. utilization turning positive after being flat earlier in the year [3] - Management noted that some elective procedures may have been advanced due to uncertainties around Medicare funding, although this has not been confirmed by third-party data [4] - Bariatric procedures are declining at high single-digit rates due to the adoption of GLP-1 therapies, highlighting that not all surgical demand is immune to therapeutic changes [5] Market Dynamics - International growth was slightly aided by holiday timing shifts, contributing approximately one percentage point to growth [4] - Hospital budget constraints, particularly outside the U.S., and macro health policy changes could impact future capital and utilization momentum [5] Valuation and Estimates - ISRG's shares have increased by 8.1% over the past six months, compared to a 14.8% rise in the industry [12] - The company trades at a forward price-to-earnings ratio of 60.4, which is above the industry average but below its five-year median of 71.52 [13] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 17.9% increase from the previous year [15]

Core Insights - Intuitive Surgical's third-quarter 2025 results indicate a shift in market-access strategy, focusing on refurbished da Vinci Xi systems to penetrate cost-sensitive markets and ambulatory surgery centers (ASCs) [1][7] - The trade-in of older da Vinci Xi systems for upgrades to da Vinci 5 is creating a reliable inventory stream for refurbished units, making them viable for budget-constrained environments [2][11] - The company is positioning refurbished Xi systems as a key growth driver in response to affordability challenges in robotic-assisted surgery [4][7] Market Strategy - Refurbished da Vinci Xi systems are being introduced as a solution for cost-sensitive buyers, both domestically and internationally, enhancing pricing and capability segmentation [3][4] - The affordability of robotic-assisted surgery is a significant barrier, particularly in the U.S. where ASCs face lower reimbursement rates [4][5] - Refurbished Xi systems allow for seamless integration into existing workflows, facilitating the transfer of procedures between hospitals and outpatient settings [5][11] International Expansion - Refurbished units serve as a strategic tool in international markets with tight government budgets and competitive pricing pressures, such as China, Japan, and parts of Europe [6][11] - The introduction of da Vinci 5 in these regions will be supported by refurbished Xi systems, fostering procedural adoption before hospitals invest in higher-end platforms [6][11] Financial Performance - Intuitive Surgical's shares have increased by 10.9% year-to-date, outperforming the industry average of 4.5% [13] - The company trades at a forward price-to-earnings ratio of 61.19, which is above the industry average but below its five-year median of 71.53 [14] - The Zacks Consensus Estimate for Intuitive Surgical's 2025 earnings suggests a 17.3% increase compared to the previous year [15]

Summary of Zimmer Biomet Conference Call Company Overview - **Company**: Zimmer Biomet - **Industry**: Orthopedic Medical Technology Key Points Market Conditions - The orthopedic markets are healthy, with a projected market size of **$4 to $4.25 billion** [2][3] - The company expects both pricing and volume to remain stable over the next two years [3] Innovation - Zimmer Biomet is transitioning from competition-centric innovation to customer-centric innovation [4] - The company is launching several new products, including: - **Anti-infective platforms** and **smart implants** [4][5] - **Solder robotics** and **autonomous robotics** [5] - The company has filled all gaps in its product portfolio, particularly in hips and knees [21] Execution Challenges - The company acknowledges inconsistent execution, with some quarters performing better than others [5][6] - Specific operational challenges were noted, including an ERP issue and unexpected order delays from Latin America and emerging markets [10][11] - The company plans to improve forecasting practices and eliminate volatile distributors [11][12] Financial Performance - In Q3, Zimmer Biomet achieved **5.6% organic growth** in the U.S., the best performance in two years [8] - The company missed revenue consensus by **$9 million** in Q3 but over-delivered on EPS [12] - The company maintains a strong balance sheet with **$1.7 billion in adjusted EBITDA** and over **$1 billion in free cash flow** [40] Guidance and Future Outlook - The company will adopt a more measured approach to quarterly guidance moving forward [12][13] - The focus will be on maintaining consistent performance and addressing operational challenges [6][7] - The company expects to see continued strong demand and pricing stability in key markets [19] Competitive Landscape - The spinoff of a major competitor, Johnson & Johnson's orthopedic business, may create market disruption that Zimmer Biomet can leverage [42][43] Product Launches and Market Strategy - Upcoming product launches include: - An **iodine-coated hip implant** in Japan, expected to command a **40%-50% premium** on pricing [29] - Full launches of **smart implants** and **solder robotics** in 2026 [23] - The company is focused on integrating recent acquisitions, including Paragon 28 and Monogram, to enhance its market position [35][40] Margin and Cost Management - Gross margins are expected to improve modestly in 2025, driven by product mix and efficiency gains [31] - The company is addressing tariff headwinds and foreign exchange pressures while focusing on revenue growth to support margin expansion [32] Capital Allocation - Zimmer Biomet is prioritizing integration of recent acquisitions and is open to opportunistic buybacks [37][40] Conclusion Zimmer Biomet is positioned to capitalize on a healthy orthopedic market through innovation and strategic execution, despite facing some operational challenges. The company is focused on maintaining consistent performance and leveraging market disruptions from competitors.